FDA approval of retinal dystrophy drug launches era of ocular gene therapy – ModernMedicine
|
FDA approval of retinal dystrophy drug launches era of ocular gene therapy
ModernMedicine In December 2017, the FDA approved voretigene neparvovec-rzyl (“voretigene,” Luxturna, Spark Therapeutics), an adeno-associated virus serotype 2 vector-based gene therapy, for the treatment of patients with confirmed biallelic RPE65 mutation-associated … |
